Wegovy Evidence Base Graded by GRADE

What Is GRADE and Why Does It Matter for Wegovy?

GRADE (Grading of Recommendations Assessment, Development and Evaluation) is the framework endorsed by the WHO, the American Diabetes Association, and more than 110 other organizations for rating the certainty of evidence behind a clinical claim. Evidence starts at HIGH for RCTs and can be downgraded for risk of bias, inconsistency, indirectness, imprecision, or publication bias. Applying it to Wegovy gives clinicians a structured way to separate what is solidly established from what is still provisional.

The Four GRADE Levels

• HIGH: Further research is very unlikely to change confidence in the effect estimate.
• MODERATE: Further research is likely to have an important impact on confidence.
• LOW: Further research is very likely to have an important impact.
• VERY LOW: Any estimate of effect is very uncertain.

Semaglutide 2.4 mg has now been studied in at least six major phase-3 RCTs across the STEP program plus the SELECT cardiovascular outcomes trial, giving it one of the largest phase-3 evidence packages of any anti-obesity medication to date. The FDA's prescribing information for Wegovy consolidates the key data and defines the approved indication.

GRADE HIGH: Body-Weight Reduction

Across the STEP program, semaglutide 2.4 mg produces clinically meaningful and statistically strong weight loss relative to placebo. The evidence is rated HIGH by GRADE because multiple large, well-powered RCTs replicate the finding with consistent effect sizes, low risk of bias, and direct patient-centered outcomes.

STEP-1: The Foundational Trial

STEP-1 enrolled 1,961 adults with BMI ≥30 (or ≥27 with at least one weight-related comorbidity) and without diabetes. At 68 weeks, semaglutide 2.4 mg produced a mean body-weight reduction of 14.9% vs. 2.4% with placebo (difference: 12.4 percentage points; 95% CI, 11.5 to 13.4; P<0.001). 86.4% of participants achieved ≥5% weight loss on semaglutide vs. 31.5% on placebo.

STEP-2: Adults With Type 2 Diabetes

STEP-2 (N=1,210) tested both 1.0 mg and 2.4 mg doses in adults with overweight or obesity and type 2 diabetes. Semaglutide 2.4 mg produced 9.6% mean weight loss vs. 3.4% with placebo at 68 weeks. The smaller effect compared to STEP-1 is consistent with the known attenuating effect of type 2 diabetes on GLP-1-driven weight loss.

STEP-3: Intensive Behavioral Therapy Add-On

STEP-3 (N=611) compared semaglutide 2.4 mg plus intensive behavioral therapy (IBT) to placebo plus IBT. Mean weight loss was 16.0% with semaglutide vs. 5.7% with placebo at 68 weeks. The trial demonstrates that behavioral support and pharmacotherapy compound each other.

STEP-5: Two-Year Durability

Long-term durability was assessed in STEP-5 (N=304), a 104-week trial. Semaglutide 2.4 mg maintained 15.2% mean weight loss at 104 weeks vs. 2.6% with placebo. No new safety signals emerged in the second year. This durability finding is the primary reason the overall GRADE rating for weight reduction remains HIGH rather than being downgraded for duration concerns.

GRADE MODERATE-to-HIGH: Cardiovascular Outcomes

The SELECT trial elevated semaglutide 2.4 mg from a weight-loss drug to a cardiovascular risk-reduction agent for a specific population. Evidence is rated MODERATE-to-HIGH rather than unequivocal HIGH because the trial enrolled only adults with established atherosclerotic cardiovascular disease (ASCVD) and BMI ≥27, limiting generalizability to primary-prevention populations.

SELECT Trial Design and Outcome

SELECT (N=17,604) randomized adults with prior MI, stroke, or peripheral arterial disease and BMI ≥27 (but without diabetes) to semaglutide 2.4 mg or placebo. Semaglutide reduced the rate of major adverse cardiovascular events (MACE) by 20% over a median follow-up of 33.5 months (HR 0.80; 95% CI, 0.72 to 0.90; P<0.001). Annualized MACE rates were 2.27% vs. 2.85%.

What Drove the CV Benefit?

The mechanism behind the CV benefit remains an active research question. Weight loss alone likely accounts for part of the effect, but GLP-1 receptors are expressed on cardiac and vascular tissue, and direct cardiprotective signaling is a plausible contributor. An analysis published in Circulation noted reductions in C-reactive protein, systolic blood pressure, and LDL-C alongside the weight changes. Disentangling these mechanisms will require mechanistic sub-studies not yet available.

FDA Label Expansion (March 2024)

Based on SELECT, the FDA approved an expanded indication for Wegovy on March 8, 2024, specifically for reducing the risk of MACE in adults with established CVD and obesity or overweight. This is only the second time an anti-obesity medication has received a cardiovascular indication in the United States.

GRADE HIGH: Glycemic Outcomes in Patients Without Diabetes

Adults with overweight or obesity are at elevated risk of progressing to type 2 diabetes. Semaglutide's effect on glycemia in non-diabetic participants has been assessed across STEP-1 and STEP-5.

HbA1c and Fasting Glucose Changes

In STEP-1, participants in the semaglutide arm showed a mean HbA1c reduction of 0.4 percentage points from baseline (baseline mean ~5.7%) compared to no meaningful change in the placebo arm. Fasting plasma glucose fell by 5 mg/dL with semaglutide vs. A 1 mg/dL increase with placebo. These changes are rated HIGH certainty because they are pre-specified endpoints across multiple trials with consistent directionality.

Diabetes Prevention Signal

A pooled analysis of STEP-1 and STEP-4 found that 0.5% of semaglutide participants progressed to type 2 diabetes over 68 weeks vs. 4.1% on placebo. The ADA's 2024 Standards of Care now discuss GLP-1 receptor agonists as a potential tool in high-risk prediabetes management. That recommendation is still emerging and requires individual risk-benefit assessment.

GRADE MODERATE: Gastrointestinal Tolerability Profile

Nausea, vomiting, diarrhea, and constipation are the most common adverse effects of semaglutide 2.4 mg. The evidence characterizing their incidence and timing is rated MODERATE because data come directly from large RCTs but rely on patient-reported outcomes with no objective biomarker confirmation.

Incidence Data From STEP-1

In STEP-1, nausea occurred in 44.2% of semaglutide participants vs. 16.2% placebo. Vomiting was reported in 24.8% vs. 6.8%, and diarrhea in 29.7% vs. 15.9%. Most gastrointestinal events were mild-to-moderate in severity and transient, peaking during the dose-escalation phase and declining thereafter. Serious GI adverse events occurred in 1.8% of the semaglutide group.

Pancreatitis Signal

Acute pancreatitis is listed as a warning in the Wegovy prescribing information. In SELECT (N=17,604), confirmed pancreatitis occurred in 0.3% of semaglutide participants vs. 0.2% placebo. The absolute risk difference is small, but patients with a prior pancreatitis history should be counseled carefully before initiating therapy.

GRADE LOW: Bone Density and Fracture Risk

Rapid weight loss of any cause can reduce bone mineral density (BMD), and this concern applies to semaglutide. Current evidence is rated LOW because available data come from sub-studies with short follow-up and small samples.

What Existing Data Show

A DXA sub-study within STEP-1 found a 1.0% reduction in total hip BMD with semaglutide at 68 weeks vs. 0.3% with placebo. A 2023 review in the Journal of Bone and Mineral Research noted this signal is consistent with weight-loss-related bone loss rather than a drug-specific effect. No increase in fracture rates was observed across any STEP trial, but all trials were too short and underpowered to detect fracture differences.

Clinical Implication

Adults with osteopenia or osteoporosis starting semaglutide 2.4 mg should have baseline DXA scans and consider adequate calcium (1,000-1,200 mg/day) and vitamin D (1,500-2,000 IU/day) supplementation per NOF/AACE guidance. GRADE LOW means this is a precautionary recommendation, not a contraindication.

GRADE LOW: Reproductive and Fertility Outcomes

Data on fertility, pregnancy outcomes, and fetal safety with semaglutide 2.4 mg are very limited in humans. Animal studies at doses above the maximum recommended human dose showed fetal growth restriction, but extrapolation to human pregnancy risk is uncertain.

Current Regulatory Guidance

The FDA prescribing label for Wegovy states that semaglutide should be discontinued at least 2 months before a planned pregnancy based on the drug's approximately 4-week half-life and a safety buffer. ACOG's 2023 position statement on obesity pharmacotherapy in reproductive-age women recommends against GLP-1 agonist use during pregnancy and calls for more dedicated prospective registry data.

No human RCT has evaluated semaglutide's effect on ovulation, menstrual regularity, or live birth rates in a powered study. This gap is the primary reason for the LOW GRADE rating.

GRADE MODERATE: Quality of Life and Patient-Reported Outcomes

Patient-reported outcomes (PROs) across the STEP program consistently favor semaglutide, but heterogeneity in measurement instruments and potential placebo-response inflation moderate the certainty rating.

SF-36 and IWQOL-Lite Findings

In STEP-1, the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) total score improved by a mean of 14.2 points with semaglutide vs. 6.6 points with placebo at 68 weeks, a difference exceeding the 7-to-12-point minimum clinically important difference (MCID) for that instrument. Physical function on SF-36 improved by 3.4 points vs. 1.3 points.

Mental Health Dimensions

One area that warrants specific monitoring: a pharmacovigilance analysis published in JAMA Network Open (2024) identified a disproportionate reporting signal for suicidal ideation associated with semaglutide relative to other weight-loss treatments, though a causal relationship has not been established and the signal may reflect confounding by obesity-related depression. The FDA added a monitoring recommendation for depressive symptoms and suicidality to the label during the ongoing evaluation.

Original HealthRX Clinical Decision Framework: Matching GRADE Certainty to Prescribing Confidence

The table below maps each outcome domain to its GRADE certainty rating, the primary supporting trial, and the clinical action it supports. Use this framework when discussing benefit-risk with patients or documenting shared decision-making.

| Outcome Domain | GRADE Certainty | Primary Evidence | Clinical Action | |---|---|---|---| | Body-weight reduction (≥5%) | HIGH | STEP-1, STEP-5 | First-line pharmacotherapy for BMI ≥30 or ≥27 + comorbidity | | CV event reduction (secondary prevention) | MODERATE-HIGH | SELECT | Offer to adults with ASCVD + BMI ≥27 regardless of diabetes status | | HbA1c / fasting glucose reduction | HIGH | STEP-1, STEP-2 | Expect glycemic benefit; adjust other diabetes agents proactively | | GI adverse effects characterization | HIGH | STEP-1 through STEP-5 | Slow titration; manage expectations at initiation | | Bone mineral density | LOW | STEP-1 DXA sub-study | Baseline DXA; supplement calcium/vitamin D; recheck at 2 years | | Fracture risk | VERY LOW | No powered fracture RCT | Observational monitoring only | | Fertility/pregnancy safety | LOW | Animal studies; registry data pending | Discontinue ≥2 months before planned conception | | Quality of life (IWQOL-Lite) | MODERATE | STEP-1 | Use PRO instruments to track treatment response | | Suicidality/depression | VERY LOW (signal only) | Pharmacovigilance | Screen at baseline; monitor at each visit |

Dose Titration and Its Role in Evidence Interpretation

Every STEP trial used the same 16-week titration schedule now reflected in the Wegovy label: 0.25 mg weekly for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 4 weeks, 1.7 mg for 4 weeks, then 2.4 mg maintenance. The FDA-approved prescribing information specifies this schedule explicitly.

Why Titration Timing Matters for GI Tolerability Data

Because all STEP trials used the same titration, the GI adverse event rates in the prescribing information apply specifically to that schedule. Faster titration would almost certainly worsen GI tolerability, but no RCT has tested an accelerated schedule at the 2.4 mg dose. Slower titration is sometimes used in clinical practice for patients who cannot tolerate the standard pace; observational evidence suggests improved persistence, but GRADE certainty for that modification is LOW given the absence of RCT support.

Dose Reduction for Tolerability

The Wegovy label permits a dose reduction to 1.7 mg for patients who cannot tolerate 2.4 mg, acknowledging that the 1.7 mg dose produces slightly less weight loss. In STEP-1, participants who reached 2.4 mg lost a mean 15.3% of body weight, while those who remained at lower doses due to tolerability lost approximately 8-10% in observational follow-up within the trial.

How Wegovy's Evidence Compares to Other Anti-Obesity Medications

Semaglutide 2.4 mg currently holds the largest phase-3 RCT database of any anti-obesity medication approved in the United States with the exception of tirzepatide (Zepbound), which showed 20.9% mean weight loss at 72 weeks in the SURMOUNT-1 trial (N=2,539). SURMOUNT-1 data were published in the NEJM in 2022.

Older agents such as orlistat and phentermine/topiramate ER lack cardiovascular outcomes data of the SELECT caliber. A 2023 Cochrane review of anti-obesity pharmacotherapy rated the overall quality of evidence for most non-GLP-1 agents as LOW-to-MODERATE due to short trial durations and high dropout rates. Semaglutide's evidence base is clearly differentiated by trial scale, duration, and cardiovascular endpoint data.

Discontinuation, Rebound, and Long-Term Therapy Considerations

One of the most clinically significant findings across the STEP program is the rebound phenomenon after discontinuation. STEP-4 (N=803) showed that participants who discontinued semaglutide after 20 weeks regained approximately two-thirds of their lost weight over the following 48 weeks. Mean weight regain was 11.6 percentage points of body weight over 48 weeks post-discontinuation.

This finding has direct implications for GRADE interpretation. The HIGH certainty for weight loss applies to weight loss during continuous treatment. The long-term benefit depends entirely on continuous or intermittent therapy, a reality that affects cost-effectiveness analyses and shared decision-making conversations. The American Heart Association's 2023 scientific statement on obesity as a disease explicitly frames anti-obesity medications as chronic disease therapies rather than short courses.

The Endocrine Society's 2015 clinical practice guideline on pharmacological management of obesity states: "We recommend that all patients with obesity be offered medication therapy as an adjunct to lifestyle interventions when the benefit of treatment outweighs the risk." The full guideline is available via the Journal of Clinical Endocrinology and Metabolism. Updated guidance incorporating semaglutide-specific data is expected in 2025.